Genocea Biosciences, Inc. (NASDAQ:GNCA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Monday.

According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “

Genocea Biosciences (GNCA) traded down 0.61% on Monday, reaching $4.91. The company’s stock had a trading volume of 122,977 shares. The firm’s 50 day moving average price is $5.76 and its 200-day moving average price is $5.35. The company’s market capitalization is $139.94 million. Genocea Biosciences has a 52 week low of $3.28 and a 52 week high of $7.29.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.06. On average, equities analysts predict that Genocea Biosciences will post ($1.89) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/17/genocea-biosciences-inc-nasdaqgnca-lowered-to-hold-at-zacks-investment-research.html.

Hedge funds have recently made changes to their positions in the company. Ameriprise Financial Inc. boosted its stake in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,068 shares during the last quarter. Keybank National Association OH bought a new stake in shares of Genocea Biosciences during the first quarter worth $147,000. Segantii Capital Management Ltd bought a new stake in shares of Genocea Biosciences during the first quarter worth $160,000. JPMorgan Chase & Co. bought a new stake in shares of Genocea Biosciences during the first quarter worth $217,000. Finally, Geode Capital Management LLC boosted its stake in shares of Genocea Biosciences by 4.7% in the first quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock worth $903,000 after buying an additional 6,708 shares during the last quarter. Institutional investors and hedge funds own 54.22% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.